Patents by Inventor Huting Wang

Huting Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • SHP2 PHOSPHATASE ALLOSTERIC INHIBITOR
    Publication number: 20220388977
    Abstract: A SHP2 phosphatase allosteric inhibitor and a drug containing said inhibitor, the SHP2 phosphatase allosteric inhibitor having the structure shown in formula (I), and the use of an optical isomer compound of the SHP2 phosphatase allosteric inhibitor or a pharmaceutically acceptable salt thereof in the preparation of drugs for the treatment of tumor diseases.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 8, 2022
    Inventors: Huting Wang, Lei Zhang, Yonggang Wang, Lixin Fan, Lei Liu, Dong Wei, Jing Wang, Jiaojiao Wang, Dongliang Mo, Mingji Jin, Yong Peng, Kun Meng
  • SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF
    Publication number: 20210300923
    Abstract: The present invention relates to a sulfoximine compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.
    Type: Application
    Filed: July 25, 2019
    Publication date: September 30, 2021
    Inventors: Jijun LI, Yan ZHU, Yeliu WANG, Xianxing SHANG, Huting WANG, Weinan HE, Qin YAN, Yinghui SUN, Kai ZHANG, Chang LU, Hongjiang XU, Xin TIAN, Ling YANG
  • TRICYCLIC COMPOUND FOR BROMODOMAIN-CONTAINING PROTEIN INHIBITOR AND PREPARATION PHARMACEUTICAL COMPOSITION, AND APPLICATION THEREOF
    Publication number: 20190040063
    Abstract: The present application present application relates to a compound represented by Formula (III) or a pharmaceutically acceptable salt, solvent compound, active metabolite, crystal polymorph, ester, isomer, or prodrug thereof. The application further provides a pharmaceutical composition comprising the compound represented by Formula (III) and a use thereof for preparing a bromodomain inhibitor for preventing or treating various diseases, such as inflammation and cancer, related to the bromodomain.
    Type: Application
    Filed: February 4, 2017
    Publication date: February 7, 2019
    Inventors: Jijun LI, Wei WU, Yan ZHU, Huting WANG, Lijia ZHAO, Welnan HE, Yinghui SUN, Yong PENG, Yongxin Han
  • KINASE ACTIVITY REGULATING COMPOUND INTERMEDIATES PREPARATION METHOD
    Publication number: 20180346418
    Abstract: The present application relates to a preparation method of intermediate compounds with formula II and formula III of a compound (N-{3-[3-(9H-purin-6-yl) pyridin-2-ylamino]-4-chloro-2-fluorophenyl}-3-fluoropropane-1-sulfonamide) for regulating kinase activity.
    Type: Application
    Filed: November 25, 2016
    Publication date: December 6, 2018
    Inventors: Jijun LI, Yan Zhu, Huting Wang, Yongxin Han, Ticong Huang, Xinlu Li, Rui Zhao, Xiquan Zhang
  • Quinazoline derivative and preparation method therefor
    Patent number: 9725439
    Abstract: The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors. The compound of the present invention can irreversibly prevent EGFR phosphorylation, and effectively depress signal transduction of cancer cells, and accordingly has higher anti-tumor activity in vitro and in vivo.
    Type: Grant
    Filed: September 28, 2014
    Date of Patent: August 8, 2017
    Assignees: CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD., CENTAURUS BIOPHARMA CO., LTD., LIANYUNGANG RUNZHONG PHARMACEUTICAL CO., LTD.
    Inventors: Dengming Xiao, Yan Zhu, Yuandong Hu, Huting Wang, Jijun Li, Yong Peng, Hui Zhang, Hong Luo, Fansheng Kong, Yongxin Han
  • Kinase modulating compounds, compositions containing the same and use thereof
    Patent number: 9550781
    Abstract: The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.
    Type: Grant
    Filed: November 14, 2012
    Date of Patent: January 24, 2017
    Assignees: Centaurus Biopharma Co., Ltd., Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Inventors: Dengming Xiao, Jijun Li, Yan Zhu, Yuandong Hu, Huting Wang, Zhe Wang, Zanping Wang, Yongheng Wei, Yinghui Sun, Qiong Wu, Hui Zhang, Yong Peng, Fansheng Kong, Ying Sun, Hong Luo, Yongxin Han
  • QUINAZOLINE DERIVATIVE AND PREPARATION METHOD THEREFOR
    Publication number: 20160214964
    Abstract: The present invention relates to a quinazoline derivative shown in formula (I) and a preparation method therefor, a pharmaceutical composition comprising the compound shown in formula (I), and an application of the compound in preparing drugs for curing and preventing tumors.
    Type: Application
    Filed: September 28, 2014
    Publication date: July 28, 2016
    Inventors: Dengming XIAO, Yan ZHU, Yuandong HU, Huting WANG, Jijun LI, Yong PENG, Hui ZHANG, Hong LUO, Fansheng KONG, Yongxin HAN
  • KINASE MODULATING COMPOUNDS, COMPOSITIONS CONTAINING THE SAME AND USE THEREOF
    Publication number: 20140296261
    Abstract: The invention provides a compound represented by formula (I) which may modulate a kinase, and a pharmaceutical composition thereof, as well as the method for preventing or treating a protein kinase mediated disease or condition.
    Type: Application
    Filed: November 14, 2012
    Publication date: October 2, 2014
    Applicants: CENTAURUS BIOPHARMA CO., LTD., CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD,
    Inventors: Dengming Xiao, Jijun Li, Yan Zhu, Yuandong Hu, Huting Wang, Zhe Wang, Zanping Wang, Yongheng Wei, Yinghui Sun, Qiong Wu, Hui Zhang, Yong Peng, Fansheng Kong, Ying Sun, Hong Luo, Yongxin Han
  • BICYCLIC HETEROARYL COMPOUNDS AS GPR119 RECEPTOR AGONISTS
    Publication number: 20140018380
    Abstract: The present invention provides a new class of bicyclic heteroaryl compounds represented by Formula I, pharmaceutical compositions containing these compounds, and their use for modulating the activity of GPR119 in the treatment of metabolic disorders and complications thereof, as well as methods for the treatment of the metabolic disorders and complications thereof.
    Type: Application
    Filed: January 31, 2012
    Publication date: January 16, 2014
    Applicant: CENTAURUS BIOPHARMA CO., LTD.
    Inventors: Dengming Xiao, Yan Zhu, Yuandong Hu, Huting Wang, Yuliang Liu, Jijun Li, Deguang Sun, Zhe Wang, Yongheng Wei, Zanping Wang, Guojing Tang, Lutao Jing